Online Course
live
28
Sep
2026
28
Sep
2026
Tumour sites
Precision oncology in breast cancer: from diagnostics to biomarker-driven treatment strategies
Background
The course will bring together an international faculty of experts to discuss the latest advances in precision oncology for HER2-positive breast cancer, from diagnostic imaging and biomarker identification to personalised treatment strategies and future clinical implementation. Through evidence-based presentations and interactive discussions, participants will gain practical insights into translating emerging evidence into multidisciplinary clinical practice.
 
Learning Objectives
- To review current and emerging diagnostic approaches in HER2-positive breast cancer.
- To discuss the role of biomarkers in patient selection and treatment planning.
- To explore personalised treatment strategies, including escalation and de-escalation approaches.
- To examine the clinical implementation of biomarker-driven precision oncology.

Main Topics
- Precision diagnostics in breast cancer
- Diagnostic biomarkers and patient selection
- Personalised treatment strategies in HER2-positive breast cancer
- Escalation and de-escalation strategies
- HER2DX and biomarker-driven clinical decision-making
- Future perspectives in precision oncology

Accreditation and Certificates
Application for CME accreditation has been submitted to the Accreditation Council of Oncology in Europe (ACOE).
Participants who fulfil the accreditation requirements (minimum attendance, completion of the evaluation questionnaire and learning assessment) will receive a certificate of attendance by email.
 
Acknowledgements
Funded by the European Union – Horizon Europe Grant Agreement No. 101136953.
Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or HADEA. Neither the European Union nor the granting authority can be held responsible for them.
This work has also received funding from the Swiss State Secretariat for Education, Research and Innovation (SERI).

28/09/2026 12:00 CEST

Welcome and introduction

Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
28/09/2026 CEST

Precision diagnostics in breast cancer

28/09/2026 12:05 CEST

From imaging to molecular characterisation

Expert: Paola Clauser, AT
28/09/2026 12:20 CEST

Current and emerging diagnostic biomarkers

Expert: Esther Sanfeliu, ES
28/09/2026 12:35 CEST

Challenges in patient selection for precision oncology

Expert: Paola Clauser, AT
28/09/2026 12:50 CEST

Discussion and Q&A

Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
Expert: Paola Clauser, AT
Expert: Esther Sanfeliu, ES
28/09/2026 CEST

Personalising treatment strategies in HER2-positive breast cancer

28/09/2026 13:00 CEST

Optimising treatment pathways in early disease

Expert: Gaia Griguolo, IT
28/09/2026 13:15 CEST

Escalation and de-escalation strategies

Expert: Monika Gräser, DE
28/09/2026 13:30 CEST

Translating evidence into multidisciplinary decision-making

Expert: Seamus O’Reilly, IE
28/09/2026 13:45 CEST

Discussion and Q&A

Chair: Matti Aapro, CH
Expert: Monika Gräser, DE
Expert: Gaia Griguolo, IT
Expert: Seamus O’Reilly, IE
28/09/2026 CEST

Biomarker-driven care: from HER2DX to future clinical implementation

28/09/2026 13:55 CEST

HER2DX in clinical practice

Expert: Marta González, ES
28/09/2026 14:10 CEST

Biomarkers and clinical trial development

Expert: Francesco Schettini, ES
28/09/2026 14:25 CEST

Future directions in precision oncology

Expert: Marta González, ES
28/09/2026 14:40 CEST

Discussion and Q&A

Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
Expert: Marta González, ES
Expert: Francesco Schettini, ES
28/09/2026 14:50 CEST

Closing remarks

Chair: Matti Aapro, CH
Chair: Seamus O’Reilly, IE
Matti Aapro
Sharing Progress in Cancer Care and Clinique de Genolier, Bellinzona and Genolier, Switzerland
Paola Clauser
Medical University of Vienna, Vienna, Austria
Marta González
Medical oncologist, Breast Cancer Research Program Fundació Clínic per a la Recerca Biomèdica (FCRB) at Hospital Clínic de Barcelona, Barcelona, Spain
Monika Gräser
Senior Consultant and Head Physician of the Breast Cancer Center Witten at Marien Hospital Witten, Witten, Germany
Gaia Griguolo
Department of Surgery, Oncology and Gastroenterology at University of Padua, Padua, Italy
Seamus O’Reilly
Consultant Medical Oncologist at Cork-Mercy and South Infirmary Victoria University Hospitals, Cork, Ireland
Esther Sanfeliu
Biomedical Diagnostic Centre (CDB), Hospital Clínic de Barcelona, Barcelona, Spain
Francesco Schettini
Medical Oncology Department at Hospital Clinic of Barcelona, Translational Genomics and Targeted Therapies in Solid Tumors Group, FRCB-IDIBAPS, Barcelona, Spain
This material is part of Educational Project:
2023-2028 DEFINITIVE project